LitCovid-sample-Enju  

PMC:7205724 / 21808-23259 JSONTXT 25 Projects

Annnotations TAB TSV DIC JSON TextAE-old TextAE

Id Subject Object Predicate Lexical cue
T54390 0-3 CD denotes 6.2
T7377 5-14 VBG denotes Targeting
T2754 15-31 JJ denotes pro-inflammatory
T79617 32-41 NNS denotes cytokines
T42975 43-48 CD denotes 6.2.1
T96891 50-60 NN denotes Hypothesis
T41163 60-61 -COLON- denotes :
T35174 62-63 DT denotes A
T74401 64-67 NN denotes mAb
T75556 68-75 IN denotes against
T83617 76-79 NN denotes IL6
T67953 80-83 MD denotes can
T68840 84-93 VB denotes attenuate
T2426 94-99 NN denotes hyper
T92661 100-112 NN denotes inflammation
T86439 113-124 NNP denotes Tocilizumab
T21494 124-125 -COMMA- denotes ,
T50157 126-130 RB denotes also
T26283 131-136 VBN denotes known
T43571 137-139 IN denotes as
T44785 140-149 NN denotes atlizumab
T96810 149-150 -COMMA- denotes ,
T58761 151-153 VBZ denotes is
T56416 154-155 DT denotes a
T79548 156-165 JJ denotes humanized
T29074 166-176 JJ denotes anti-human
T88685 177-180 NN denotes IL6
T26777 181-189 NN denotes receptor
T24185 190-198 NN denotes antibody
T17221 199-207 VBN denotes approved
T32471 208-210 IN denotes by
T53882 211-214 NNP denotes FDA
T24580 215-218 IN denotes for
T33924 219-226 JJ denotes several
T90119 227-239 JJ denotes inflammatory
T59846 240-243 CC denotes and
T31666 244-254 JJ denotes autoimmune
T46803 255-263 NNS denotes diseases
T80969 264-270 JJ denotes severe
T13017 270-271 -COMMA- denotes ,
T79015 272-276 JJ denotes such
T43255 277-279 IN denotes as
T47553 280-288 NN denotes cytokine
T34694 289-296 NN denotes release
T36705 297-305 NN denotes syndrome
T68837 305-306 -COMMA- denotes ,
T30269 307-317 JJ denotes rheumatoid
T54700 318-327 NN denotes arthritis
T81658 327-328 -COMMA- denotes ,
T84650 329-334 JJ denotes giant
T11095 335-339 NN denotes cell
T15987 340-349 NN denotes arteritis
T88887 349-350 -COMMA- denotes ,
T31599 351-364 JJ denotes polyarticular
T93322 365-373 JJ denotes juvenile
T49595 374-384 JJ denotes idiopathic
T62141 385-394 NN denotes arthritis
T76737 394-395 -COMMA- denotes ,
T30470 396-399 CC denotes and
T13999 400-410 JJ denotes systematic
T88238 411-419 JJ denotes juvenile
T89892 420-430 JJ denotes idiopathic
T97598 431-440 NN denotes arthritis
T25454 442-444 PRP denotes It
T28665 445-447 VBZ denotes is
T15312 448-452 JJ denotes safe
T18121 453-456 CC denotes and
T2467 457-466 JJ denotes effective
T39207 467-470 IN denotes for
T89869 471-475 DT denotes both
T32842 476-482 NNS denotes adults
T38357 483-486 CC denotes and
T13891 487-495 NNS denotes children
T61388 496-499 CD denotes two
T66576 500-505 NNS denotes years
T46590 506-508 IN denotes of
T15404 509-512 NN denotes age
T19164 513-516 CC denotes and
T99851 517-522 JJR denotes older
T41884 525-530 CD denotes 6.2.2
T3706 532-541 NNP denotes Rationale
T87509 541-542 -COLON- denotes :
T72411 543-554 NNP denotes Tocilizumab
T46139 555-558 MD denotes can
T80638 559-564 VB denotes treat
T14365 565-569 NN denotes lung
T88114 570-576 NN denotes injury
T76208 577-579 IN denotes in
T24628 580-588 NNS denotes patients
T15777 589-593 IN denotes with
T58130 594-602 JJ denotes critical
T31522 603-606 CC denotes and
T55163 607-613 JJ denotes severe
T92225 614-622 NN denotes COVID-19
T21073 623-625 IN denotes In
T65150 626-629 DT denotes the
T61991 630-635 NN denotes study
T18474 636-637 -LRB- denotes [
T8341 637-639 CD denotes 27
T6430 639-640 -RRB- denotes ]
T29393 640-641 -COMMA- denotes ,
T77821 642-644 CD denotes 21
T79215 645-653 NNS denotes patients
T5404 654-658 IN denotes with
T75582 659-667 NN denotes COVID-19
T89299 668-673 WP-DOLLAR- denotes whose
T66055 674-683 NN denotes condition
T80340 684-687 VBD denotes was
T3490 688-694 JJ denotes severe
T44653 695-697 CC denotes or
T55941 698-706 JJ denotes critical
T85453 707-715 VBD denotes received
T98598 716-719 CD denotes one
T96881 720-722 CC denotes or
T24534 723-726 CD denotes two
T70238 727-732 NNS denotes doses
T20616 733-735 IN denotes of
T68912 736-747 NNP denotes Tocilizumab
T98192 748-752 CC denotes plus
T20706 753-761 JJ denotes standard
T58005 762-769 NN denotes therapy
T96625 771-779 NNS denotes Patients
T75572 780-783 WP denotes who
T31917 784-787 VBD denotes had
T15301 788-789 DT denotes a
T24848 790-794 JJ denotes mean
T84688 795-798 NN denotes IL6
T96963 799-804 NN denotes level
T6930 805-807 IN denotes of
T90933 808-812 JJR denotes more
T81944 813-817 IN denotes than
T75581 818-827 NN denotes 100 pg/ml
T64021 828-834 IN denotes before
T9387 835-846 NN denotes tocilizumab
T84664 847-856 NN denotes treatment
T18203 857-863 VBD denotes showed
T60803 864-875 NN denotes improvement
T44490 876-878 IN denotes in
T81402 879-887 JJ denotes clinical
T14228 888-896 NNS denotes symptoms
T94537 897-900 CC denotes and
T83697 901-911 JJ denotes peripheral
T13978 912-918 NN denotes oxygen
T35808 919-929 NN denotes saturation
T34900 930-933 CC denotes and
T75964 934-947 NN denotes normalization
T84268 948-951 IN denotes for
T65028 952-962 NN denotes lymphocyte
T34390 963-973 NN denotes proportion
T96610 974-977 CC denotes and
T30755 978-981 NN denotes CRP
T63070 982-988 NNS denotes levels
T31791 990-994 RB denotes Also
T31152 994-995 -COMMA- denotes ,
T79595 996-1000 NN denotes lung
T51431 1001-1007 NN denotes lesion
T10130 1008-1015 NN denotes opacity
T31388 1016-1019 VBD denotes was
T1824 1020-1028 VBN denotes absorbed
T60055 1029-1031 IN denotes in
T38598 1032-1034 CD denotes 90
T67288 1034-1035 NN denotes %
T48683 1036-1038 IN denotes of
T41529 1039-1047 NNS denotes patients
T69670 1049-1056 CC denotes Neither
T9277 1057-1064 JJ denotes serious
T15021 1065-1072 JJ denotes adverse
T23626 1073-1080 NNS denotes effects
T98539 1081-1084 CC denotes nor
T65699 1085-1091 NNS denotes deaths
T50204 1092-1100 VBD denotes occurred
T20973 1101-1105 IN denotes with
T14012 1106-1117 NN denotes tocilizumab
T66286 1118-1127 NN denotes treatment
T24269 1129-1134 EX denotes There
T26765 1135-1138 VBP denotes are
T84711 1139-1146 VBG denotes ongoing
T74304 1147-1155 JJ denotes clinical
T68003 1156-1162 NNS denotes trials
T5000 1163-1166 IN denotes for
T64198 1167-1178 NN denotes tocilizumab
T83078 1179-1188 NN denotes treatment
T11331 1189-1191 IN denotes in
T42834 1192-1200 NNS denotes patients
T27205 1201-1205 IN denotes with
T23786 1206-1214 JJ denotes moderate
T45333 1215-1218 CC denotes and
T9137 1219-1225 JJ denotes severe
T27842 1226-1234 NN denotes COVID-19
T92236 1236-1245 RB denotes Currently
T32112 1245-1246 -COMMA- denotes ,
T54987 1247-1250 DT denotes the
T85855 1251-1254 NN denotes use
T69355 1255-1257 IN denotes of
T40115 1258-1269 NNP denotes Tocilizumab
T10850 1270-1272 VBZ denotes is
T78367 1273-1284 VBN denotes recommended
T33042 1285-1288 IN denotes for
T36466 1289-1297 NNS denotes patients
T61983 1298-1302 IN denotes with
T2749 1303-1311 NN denotes COVID-19
T17580 1312-1315 WP denotes who
T69055 1316-1320 VBP denotes have
T71996 1321-1328 VBG denotes warning
T59356 1329-1334 NNS denotes signs
T65527 1335-1337 IN denotes of
T99769 1338-1343 NN denotes hyper
T44301 1344-1356 NN denotes inflammation
T54453 1356-1357 -COMMA- denotes ,
T58078 1358-1360 IN denotes as
T75237 1361-1364 MD denotes can
T7496 1365-1367 VB denotes be
T53845 1368-1376 VBN denotes measured
T78207 1377-1379 IN denotes by
T88455 1380-1383 NN denotes IL6
T77671 1383-1384 -COMMA- denotes ,
T67481 1385-1393 NN denotes ferritin
T99390 1393-1394 -COMMA- denotes ,
T23484 1395-1403 NN denotes platelet
T65701 1404-1410 NNS denotes counts
T30323 1410-1411 -COMMA- denotes ,
T72053 1412-1424 JJ denotes inflammatory
T81575 1425-1432 NNS denotes markers
T96428 1432-1433 -COMMA- denotes ,
T36542 1434-1437 CC denotes and
T88469 1438-1439 NN denotes H
T51141 1440-1445 NN denotes score
T97739 1446-1447 -LRB- denotes [
T29313 1447-1449 CD denotes 28
T54016 1449-1450 -RRB- denotes ]
R10896 T63070 T65028 arg1Of levels,lymphocyte
R12091 T60803 T44490 arg1Of improvement,in
R12170 T62141 T88887 arg2Of arthritis,","
R12475 T15987 T11095 arg1Of arteritis,cell
R13130 T30755 T96610 arg2Of CRP,and
R13146 T26283 T50157 arg1Of known,also
R13154 T85855 T7496 arg1Of use,be
R13264 T44301 T99769 arg1Of inflammation,hyper
R13465 T46803 T33924 arg1Of diseases,several
R14004 T66055 T89299 arg1Of condition,whose
R14765 T96891 T68840 arg1Of Hypothesis,attenuate
R15083 T36542 T96428 arg1Of and,","
R15531 T77671 T99390 arg1Of ",",","
R16905 T68003 T84711 arg1Of trials,ongoing
R17601 T27842 T27205 arg2Of COVID-19,with
R18021 T53882 T17221 arg1Of FDA,approved
R19206 T53845 T78207 arg1Of measured,by
R19260 T54700 T68837 arg2Of arthritis,","
R19276 T24185 T56416 arg1Of antibody,a
R19638 T30470 T76737 arg1Of and,","
R20598 T55163 T31522 arg2Of severe,and
R20734 T80969 T24580 arg2Of severe,for
R20864 T81658 T88887 arg1Of ",",","
R21368 T24628 T15777 arg1Of patients,with
R21524 T24185 T26777 arg1Of antibody,receptor
R21619 T34900 T94537 arg2Of and,and
R21959 T36705 T34694 arg1Of syndrome,release
R21977 T81575 T30323 arg2Of markers,","
R22400 T44301 T65527 arg2Of inflammation,of
R22449 T98539 T69670 arg1Of nor,Neither
R2263 T24185 T88685 arg1Of antibody,IL6
R2282 T67481 T77671 arg2Of ferritin,","
R23852 T97598 T89892 arg1Of arthritis,idiopathic
R24087 T24185 T79548 arg1Of antibody,humanized
R24341 T43255 T79015 arg1Of as,such
R24887 T35808 T13978 arg1Of saturation,oxygen
R24950 T38357 T99851 arg1Of and,older
R25403 T3490 T44653 arg1Of severe,or
R26554 T83078 T5000 arg2Of treatment,for
R2665 T97598 T13999 arg1Of arthritis,systematic
R26904 T85855 T78367 arg2Of use,recommended
R27191 T23626 T98539 arg1Of effects,nor
R27294 T1824 T31388 arg2Of absorbed,was
R27449 T83078 T64198 arg1Of treatment,tocilizumab
R27501 T51141 T36542 arg2Of score,and
R2759 T62141 T31599 arg1Of arthritis,polyarticular
R27739 T61991 T21073 arg2Of study,In
R27887 T17221 T24580 arg1Of approved,for
R28465 T23786 T45333 arg1Of moderate,and
R29264 T44653 T80340 arg2Of or,was
R29518 T68003 T5000 arg1Of trials,for
R29604 T88114 T80638 arg2Of injury,treat
R30062 T42834 T27205 arg1Of patients,with
R3039 T79215 T5404 arg1Of patients,with
R31375 T75582 T5404 arg2Of COVID-19,with
R32577 T74401 T41163 arg2Of mAb,:
R33248 T30470 T43255 arg2Of and,as
R33385 T25454 T15312 arg1Of It,safe
R33791 T99851 T19164 arg2Of older,and
R34037 T68003 T74304 arg1Of trials,clinical
R34196 T13891 T38357 arg2Of children,and
R35135 T36466 T69055 arg1Of patients,have
R37231 T98539 T50204 arg1Of nor,occurred
R37501 T66576 T61388 arg1Of years,two
R37530 T80638 T46139 arg2Of treat,can
R37793 T96625 T75572 arg1Of Patients,who
R40933 T36542 T78207 arg2Of and,by
R41615 T51141 T97739 arg1Of score,[
R41949 T36705 T68837 arg1Of syndrome,","
R42046 T15987 T84650 arg1Of arteritis,giant
R42123 T70238 T85453 arg2Of doses,received
R42821 T97598 T88238 arg1Of arthritis,juvenile
R42879 T98539 T9277 arg1Of nor,serious
R4444 T31666 T59846 arg2Of autoimmune,and
R4477 T92225 T55163 arg1Of COVID-19,severe
R44975 T10130 T1824 arg2Of opacity,absorbed
R45357 T36705 T47553 arg1Of syndrome,cytokine
R45661 T90933 T64021 arg1Of more,before
R47508 T97598 T30470 arg2Of arthritis,and
R48338 T24185 T58761 arg2Of antibody,is
R48681 T61991 T18474 arg1Of study,[
R48731 T59356 T69055 arg2Of signs,have
R4907 T85855 T10850 arg1Of use,is
R49421 T1824 T60055 arg1Of absorbed,in
R50655 T88887 T30470 arg1Of ",",and
R50965 T66286 T14012 arg1Of treatment,tocilizumab
R51850 T94537 T18203 arg2Of and,showed
R52999 T66055 T80340 arg1Of condition,was
R53041 T58078 T92236 arg1Of as,Currently
R53068 T96963 T31917 arg2Of level,had
R53187 T96963 T24848 arg1Of level,mean
R5373 T90933 T6930 arg2Of more,of
R53734 T24534 T96881 arg2Of two,or
R54223 T78367 T10850 arg2Of recommended,is
R5554 T60803 T94537 arg1Of improvement,and
R56159 T50204 T20973 arg1Of occurred,with
R56313 T62141 T93322 arg1Of arthritis,juvenile
R56743 T98192 T20616 arg2Of plus,of
R57258 T90933 T81944 arg1Of more,than
R5731 T70238 T24534 arg1Of doses,two
R57671 T62141 T49595 arg1Of arthritis,idiopathic
R57903 T63070 T34390 arg1Of levels,proportion
R58214 T53882 T32471 arg2Of FDA,by
R58839 T74401 T75556 arg1Of mAb,against
R59110 T29313 T97739 arg2Of 28,[
R59437 T54700 T30269 arg1Of arthritis,rheumatoid
R59576 T9137 T45333 arg2Of severe,and
R60119 T36466 T17580 arg1Of patients,who
R60586 T65701 T99390 arg2Of counts,","
R60939 T90119 T59846 arg1Of inflammatory,and
R61251 T2749 T61983 arg2Of COVID-19,with
R61440 T58005 T98192 arg2Of therapy,plus
R61441 T58078 T32112 arg1Of as,","
R6154 T59356 T65527 arg1Of signs,of
R61551 T14228 T81402 arg1Of symptoms,clinical
R62752 T34900 T84268 arg1Of and,for
R63345 T18121 T28665 arg2Of and,is
R64318 T65699 T98539 arg2Of deaths,nor
R6462 T44785 T43571 arg2Of atlizumab,as
R64820 T96891 T41163 arg1Of Hypothesis,:
R65301 T58761 T96810 arg1Of is,","
R65601 T70238 T20616 arg1Of doses,of
R65763 T25454 T28665 arg1Of It,is
R65895 T24185 T29074 arg1Of antibody,anti-human
R66809 T14228 T44490 arg2Of symptoms,in
R66943 T85855 T54987 arg1Of use,the
R66954 T24269 T26765 arg1Of There,are
R67132 T70238 T98598 arg1Of doses,one
R67692 T75964 T34900 arg2Of normalization,and
R68271 T30323 T36542 arg1Of ",",and
R69456 T24628 T76208 arg2Of patients,in
R69719 T79617 T2754 arg1Of cytokines,pro-inflammatory
R71645 T15312 T18121 arg1Of safe,and
R71674 T85855 T75237 arg1Of use,can
R72696 T83617 T75556 arg2Of IL6,against
R72772 T59356 T71996 arg1Of signs,warning
R72983 T78367 T54453 arg1Of recommended,","
R74424 T98598 T96881 arg1Of one,or
R74784 T68840 T67953 arg2Of attenuate,can
R74963 T79215 T85453 arg1Of patients,received
R75326 T85453 T21073 arg1Of received,In
R75716 T54390 T7377 arg1Of 6.2,Targeting
R75826 T96963 T15301 arg1Of level,a
R76104 T41529 T48683 arg2Of patients,of
R76550 T58130 T31522 arg1Of critical,and
R76769 T92225 T58130 arg1Of COVID-19,critical
R76811 T26283 T43571 arg1Of known,as
R77190 T66576 T19164 arg1Of years,and
R77316 T54016 T97739 arg3Of ],[
R77360 T38357 T89869 arg1Of and,both
R77534 T24185 T17221 arg2Of antibody,approved
R78022 T66055 T55941 arg1Of condition,critical
R78333 T32842 T38357 arg1Of adults,and
R78533 T42834 T11331 arg2Of patients,in
R78642 T84664 T9387 arg1Of treatment,tocilizumab
R79228 T79215 T77821 arg1Of patients,21
R79527 T74401 T35174 arg1Of mAb,A
R79687 T92225 T15777 arg2Of COVID-19,with
R79824 T2467 T18121 arg2Of effective,and
R79844 T68837 T81658 arg1Of ",",","
R79916 T84664 T64021 arg2Of treatment,before
R79941 T66286 T20973 arg2Of treatment,with
R80450 T8341 T18474 arg2Of 27,[
R80686 T66576 T46590 arg1Of years,of
R81194 T55941 T44653 arg2Of critical,or
R81304 T38357 T39207 arg2Of and,for
R8185 T96625 T18203 arg1Of Patients,showed
R81985 T1824 T31791 arg1Of absorbed,Also
R8244 T63070 T84268 arg2Of levels,for
R82868 T86439 T26283 arg2Of Tocilizumab,known
R82985 T80638 T76208 arg1Of treat,in
R82994 T61991 T65150 arg1Of study,the
R83125 T86439 T21494 arg1Of Tocilizumab,","
R83390 T51141 T88469 arg1Of score,H
R84073 T96891 T67953 arg1Of Hypothesis,can
R84172 T75582 T89299 arg2Of COVID-19,whose
R84332 T3706 T87509 arg1Of Rationale,:
R84932 T53845 T7496 arg2Of measured,be
R85183 T98539 T15021 arg1Of nor,adverse
R85448 T38357 T66576 arg1Of and,years
R85482 T78367 T58078 arg1Of recommended,as
R85705 T67288 T38598 arg1Of %,90
R86004 T72411 T46139 arg1Of Tocilizumab,can
R86212 T46803 T90119 arg1Of diseases,inflammatory
R86934 T18121 T39207 arg1Of and,for
R87485 T46803 T31666 arg1Of diseases,autoimmune
R87538 T85855 T53845 arg2Of use,measured
R87665 T25454 T2467 arg1Of It,effective
R88261 T96963 T84688 arg1Of level,IL6
R88299 T63070 T30755 arg1Of levels,CRP
R89076 T88455 T77671 arg1Of IL6,","
R89241 T27842 T23786 arg1Of COVID-19,moderate
R89881 T85855 T69355 arg1Of use,of
R89899 T68912 T98192 arg1Of Tocilizumab,plus
R8993 T65701 T23484 arg1Of counts,platelet
R89954 T67288 T60055 arg2Of %,in
R9002 T3706 T41884 arg1Of Rationale,6.2.2
R90450 T10130 T31388 arg1Of opacity,was
R90482 T88114 T14365 arg1Of injury,lung
R90538 T46803 T80969 arg1Of diseases,severe
R90654 T66055 T3490 arg1Of condition,severe
R90774 T35808 T34900 arg1Of saturation,and
R90910 T1824 T31152 arg1Of absorbed,","
R91084 T67288 T48683 arg1Of %,of
R91228 T96625 T31917 arg1Of Patients,had
R91756 T86439 T58761 arg1Of Tocilizumab,is
R92122 T81575 T72053 arg1Of markers,inflammatory
R92175 T15404 T46590 arg2Of age,of
R92198 T72411 T80638 arg1Of Tocilizumab,treat
R92270 T96891 T42975 arg1Of Hypothesis,6.2.1
R92393 T35808 T83697 arg1Of saturation,peripheral
R92489 T40115 T69355 arg2Of Tocilizumab,of
R92565 T99390 T30323 arg1Of ",",","
R92610 T24185 T43255 arg1Of antibody,as
R92720 T36466 T61983 arg1Of patients,with
R93465 T79617 T7377 arg2Of cytokines,Targeting
R93944 T78367 T33042 arg1Of recommended,for
R94262 T68003 T26765 arg2Of trials,are
R94310 T53845 T58078 arg2Of measured,as
R94369 T75581 T81944 arg2Of 100 pg/ml,than
R94556 T92661 T68840 arg2Of inflammation,attenuate
R95470 T83078 T11331 arg1Of treatment,in
R96088 T96963 T6930 arg1Of level,of
R96842 T53845 T75237 arg2Of measured,can
R96846 T15987 T81658 arg2Of arteritis,","
R96954 T36466 T33042 arg2Of patients,for
R97104 T27842 T9137 arg1Of COVID-19,severe
R97168 T34390 T96610 arg1Of proportion,and
R97353 T58005 T20706 arg1Of therapy,standard
R97819 T17221 T13017 arg1Of approved,","
R98220 T85453 T29393 arg1Of received,","
R98822 T92661 T2426 arg1Of inflammation,hyper
R9904 T10130 T51431 arg1Of opacity,lesion
R99138 T10130 T79595 arg1Of opacity,lung
R99891 T6430 T18474 arg3Of ],[